Loading stock…

Regencell Bioscience Holdings Limited (RGC) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Regencell Bioscience Holdings Limited

RGCMarket cap $3.64BPrice $7.3

Country🇭🇰Hong Kong

SectorHealthcare

IndustryPharmaceuticals

Develops traditional Chinese medicine therapies targeting neurocognitive disorders like ADHD and autism. This tiny Hong Kong biotech briefly hit a market cap larger than most established pharma giants in 2025, despite having zero approved products on the market.

In Bastion Portfolios?

52W Return-58%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)na–

Revenue Forecast

Rev CAGR (1y)na–

Rev CAGR (3y)na–

Rev CAGR (5y)na–

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2na–

EPS Growth Y+3na–

Quality

Margins

EBIT Marginna–

Net Income Marginna–

Free Cash Flow Marginna–

Debt

Net Debt/EBITDA0.37

Efficiency

ROE-178%1

ROA-134%1

Earnings Stability22

GEAR+

Not enough data to calculate the GEAR+ rating.

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV2986.51

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-0.1%3

Dividend Yieldna–

Momentum

Short term

1 month return+7%10

3 month return+24%10

YTD return-65%1

Mid term

Price vs 52wHigh11%1

1 year return-63%1

Long term

3 year return+1487%10

5 year return+1318%10

Risk Shield

Price Risk

Beta-1.010

Volatility139%1

Free Cash Flow

Free Cash Flow Marginna–

Free Cash Flow Yield-0.1%3

Quality

ROCE-162%1

Earnings Stability22

Net Debt/EBITDA0.37

02Growth

Is it actually growing, and how fast?

Revenue

No data

GROWTH RATING↗

——

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Yna–

Revenue, next 3Y, CAGRna–

Revenue, next 5Y, CAGRna–

EARNINGS FORECAST▾SCORE

EPS growth, FY+10%5

EPS growth, FY+2na–

EPS growth, FY+3na–

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue held flat over the last 3 years and is set to keep growing around 0%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 100% of companies worldwide.

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

RGCRegencell Bioscience Holdings

Total return Current707%

Price return Current707%

MOMENTUM RATING↗

STRONG72 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+7%10

3-month return+24%10

YTD return-65%1

MID & LONG-TERM▾SCORE

% of 52-week high11%1

1-year return-63%1

3-year return+1487%10

5-year return+1318%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +1487% over three years and +1318% over five, ahead of 90% of the market.

Strong recent results. The stock is outperforming over the past month (+7%) and over three months (+24%).

WATCH

None flagged.

WEAKNESSES

It's down 63% over the past year, now 89% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-65%).

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Regencell Bioscience Holdings Limited. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

Revenue

No data

GROWTH RATING↗

——

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Yna–

Revenue, next 3Y, CAGRna–

Revenue, next 5Y, CAGRna–

EARNINGS FORECAST▾SCORE

EPS growth, FY+10%5

EPS growth, FY+2na–

EPS growth, FY+3na–

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue held flat over the last 3 years and is set to keep growing around 0%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 100% of companies worldwide.

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

RGCRegencell Bioscience Holdings

Total return Current707%

Price return Current707%

MOMENTUM RATING↗

STRONG72 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+7%10

3-month return+24%10

YTD return-65%1

MID & LONG-TERM▾SCORE

% of 52-week high11%1

1-year return-63%1

3-year return+1487%10

5-year return+1318%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +1487% over three years and +1318% over five, ahead of 90% of the market.

Strong recent results. The stock is outperforming over the past month (+7%) and over three months (+24%).

WATCH

None flagged.

WEAKNESSES

It's down 63% over the past year, now 89% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-65%).

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Regencell Bioscience Holdings Limited. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community